Citadel Advisors
SQZ

Citadel Advisors’s SQZ Biotechnologies Company SQZ Stock Holding History

Citadel Advisors’s Portfolio SQZ Stock Details SQZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500
Closed -$280 – 15611
2023
Q1 		$280 Buy
+500
New +$368 ﹤0.01% 14531

Other funds holding SQZ

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's SQZ Position: Q4 2022 in Review

Citadel Advisors sold out of SQZ Biotechnologies Company (SQZ) in Q4 2022, closing a stake of 16,891 shares — an estimated $38K sold.

Citadel Advisors first reported a position in SQZ in Q4 2021 and held it in 4 quarters. The position peaked at $201K in Q2 2022. 36 funds tracked by Wall St. Rank hold SQZ as of Q4 2022.

  • Citadel Advisors reported no remaining SQZ Biotechnologies Company position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 16,891 SQZ Biotechnologies Company shares in Q4 2022, an estimated $38K.
  • Citadel Advisors first reported a position in SQZ Biotechnologies Company in Q4 2021 and held it in 4 quarters.
  • Citadel Advisors's SQZ Biotechnologies Company position peaked at $201K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.